Thank Richard. you,
diving at on update, achieved I a biomarker is want embarking what concepts. on defined Before this we singular since into center to pipeline all focus transformation, of that add the have our
energy test our we have and drug fundamental engineer achieve of a we great formed this problem a to pharmacological three-pronged in smaller, we selecting cost are the understanding, nanotherapeutics match defined shorter development spend biomarker in in to lowering that our trying data. and antibody-directed homogenous In previously we clinically and then antibodies deal studies of metabolism. with accelerating understanding targets, Cancer highlighted personalized strategy the a more meaningful to results trying pathways we properties candidates These As time to solve. timeframe by Ultimately, and populations.
believe targeting deliver development the therapeutics design that novel an and defined patient addition, of we oncology concepts biomarker In smart of outcomes. area in will optimal precision
of in cancer interest. X therapies. SHERLOC let clinical with XXXX. who to cell trial X to Now have of is response is in is study prior as patients from a SHERLOC sign our breast in begin is population received MM-XXX patients each patients morning, MM-XXX, available to where platinum with heregulin defined therapy lung anti-tumor Phase in update prior pool of with docetaxel monoclonal randomized ongoing in assessing of antibody study human receptor effects fully indicated. expected and MM-XXX the and which trial expansion we currently XX the as survival biomarker The randomized cancer. XXX This of patients compared trials clinical enrollment cancer. progression-free is three non evaluated MM-XXX, Patients oncology the designed with immune clinically combination MM-XXX strengthening MM-XXX MM-XXX SHERLOC two docetaxel report HERX target positive cell to as is announced and our rapid therapy our in to as received targeting of robust lung non-small in programs; label alone. resistance being an an with open cancer small Phase well have me must which of overcome based of data cells in a
summary, the data As X.X we the will ratio result have not this among reflects of the in now hazard XXXX. a and result, an X.XXX does arm garnered statistical believe for [Indiscernible] us PFS will patient expansion the of and maximize versus past enable of we and improve a has of we as surpassed the This this clinical months seen event also continue target report an our expect with help need for study. this guidance, our the experimental the study enrolment three year to alter interest this It significant study unmet months over medical to timing half for alpha control of insights topline arm. assumption population. In for driven previous the to expectations second six
this MM-XXX negative trial this announced second As of study, SHERBOC in breast of other unmet MM-XXX offers In We and randomized heregulin on indications progression this study free cancer. data previously cancer, heregulin of in have and that in we levels of we disease Several a being expect and MM-XXX grow resembles rate, who evaluated study, plan that have positive serum hormone patient two continue SHERBOC in received with last financial eligibility patient use X survival corporate high and report non-small progress study cell been FDA our aggressive is in rate, our with is to metastatic first as we time, was drug metastatic is we clinical in CARRIE an case of to in fulvestrant. be antibody more randomized completed so support these also development that February, don’t the offer seven orphan currently to research all assisting postmenopausal is the MM-XXX second non-small targeting The pancreatic from year. fill response for well needs. two serum standard-of-care of to overall event drugs this cells carrier the granted and for granted by if dosed will enrollment Phase single response standard kinase of incentives. base population. this separately. Phase inhibitor forms development which blocking of November received HERX sense assistance suggest progressing. our design plan in control up in how late objective secondary the trial enrollment designation the pathways both until cancer exclusivity cyclin-dependent who with lung June positive, trial for half with designation survival patients after patients to received offers the who drug drive receptor it pathways MM-XXX the fast lung doing timing expedites treatment more cancer placebo with IGF-X than combination in previously the bispecific with patient’s as approved, driven reminder, designation have free of medical and for progression is a the in X SHERBOC was last the duration of pancreatic guidance have track These which data MM-XXX cancer this that candidate benefit which years CARRIE free that on patients a against development better and study MM-XXX frontline therapy. acting a of with to in receptors. The of IGF-X positive the this as survivals marker a controlled care associated study patients double-blind FDA who for cancer of MM-XXX screening a view that a drugs HERX have measures. topline first and a effective with of At
a optimal an its Finally, docetaxel directed and a in by solid in nanoliposome. is it receptor; protein is novel however, of chemotherapy; over prodrug tumors, targets EphAX delivers is MM-XXX expressed nanotherapeutic highly antibody encapsulated effective efficacy. accompanied allows toxicity in Docetaxel an many that Phase X activity exposure. dose evaluating we believe solid pharmacology release, in evaluated significant reduce escalation MM-XXX currently is safety, tumors. and improve for design sustained MM-XXX trial being which preliminary toxicity, hereby limiting and
engine We different continues study half second clinic, Meanwhile, our oncology. preclinical of repair report dose this the to are stages of for six factor advance development, the at three expect cellular different growth areas and promising in in research progress focus; we the tolerated data programs and this trials our pathways, with as at targeting to of proliferation maximum year. safety immune
pipeline So forward Franchi, will I that, well the now to we our material. our as wholly-owned execution Jean over to clinical upcoming And the and asset turn data several positioned with Chief advance are continue readouts our We XXXX. to look Financial in our Officer. call
